Sera Prognostics, Inc. Class A Common Stock (SERA) Stock Price
SERAStock
$2.06−38.32%52W
Market Cap$81.27M
P/E—
PEG Ratio—
Div yield—
Beta1.09
SERA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-13.64%
Price vs S&P 500 (4W)-1.51%
VGM Score41.16
SERA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.16 | -$0.18 | -12.50%(-$0.02) | |
| Q1 2026 | -$0.17 | -$0.17 | +1.92%(+$0.00) | |
| Q4 2025 | -$0.19 | -$0.16 | +15.79%(+$0.03) | |
| Q3 2025 | -$0.21 | -$0.16 | +23.81%(+$0.05) | |
| Q2 2025 | -$0.24 | -$0.16 | +33.33%(+$0.08) |
SERA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.33
4.30
4.30
4.30
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
SERASera Prognostics, Inc. Class A Common Stock | D | C | C | — | -35.2% | -53282.9% | -46.7% | $2.06 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
About Sera Prognostics, Inc. Class A Common Stock
Sera Prognostics develops blood-based diagnostic tests that predict individualized maternal health risks, including premature birth, preeclampsia, gestational diabetes, and stillbirth. Using proprietary proteomics and bioinformatics technology, the company commercializes biomarker tests and predictive analytics products to improve maternal and neonatal health outcomes.